Drug Trial Radar · NCT07046923
A Study of LY4175408 in Participants With Advanced Cancer
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Jul 28, 2025
Primary completion
Jul 2030
Study completion Jul 2030
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jul 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.
Conditions
- Carcinoma, Non-Small-Cell Lung
- Small Cell Lung Carcinoma
- Endometrial Neoplasms
- Neoplasm Metastasis
- Triple Negative Breast Cancer
Interventions
LY4175408Drug
IV infusion
PembrolizumabDrug
IV infusion
CarboplatinDrug
IV infusion
CisplatinDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a-Number of Participants with Dose Limiting Toxicities of LY4175408Time frame: 1 Cycle (21 days)
- Phase 1b-Overall Response Rate (ORR): Percentage of Participants with Best Response of Complete Response (CR) or Partial Response (PR)Time frame: Baseline up to approximately 4 years
Locations
24 sites in 5 countries. Site status is shown where the registry gives one.
Stanford Medicine Cancer Center
Stanford, California
Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute
Orlando, Florida
Florida Cancer Specialists - Sarasota
Sarasota, Florida
The University of Chicago Medical Center (UCMC)
Chicago, Illinois
Community Health Network
Indianapolis, Indiana
Massachusetts General Hospital
Boston, Massachusetts
Washington University
St Louis, Missouri
John Theurer Cancer Center At Hackensack UMC
Hackensack, New Jersey
Columbia University
New York, New York
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York
The Ohio State University (OSU) Wexner Medical Center
Columbus, Ohio
Sarah Cannon Research Institute
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
START Mountain Region
West Valley City, Utah
NEXT Virginia
Fairfax, Virginia
Centre Leon Berard
Lyon, France
Institut Gustave Roussy
Villejuif, France
Kyoto University Hospital
Kyoto, Japan
National Cancer Center Hospital
Tokyo, Japan
Cancer Institute Hospital of JFCR
Tokyo, Japan
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.